EUVIMEDEUVIMED entdecken
Crossref

Discovery of a potent thienodiazepine derivative as a novel BRD4 degrader

Mayu Shigekuni, Yasuki Niwa, Kiyomi Ohba, Maiko Hamada, Hideto Maruyama, Shiki Miyazaki, Daisuke Iijima, Shinsuke Ooike, Ryo Fujita, Yasufumi Fukano, Tsuyoshi Takahashi, Nao Torimoto und 4 weitere

Bioorganic & Medicinal Chemistry · 2026

DOI: 10.1016/j.bmc.2026.118583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026. Verfasst von Mayu Shigekuni und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: mayu.shigekuni@tanabe-pharm…. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Transcription Factors, Antineoplastic Agents, Drug Discovery. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We discovered bromodomain-containing protein 4 (BRD4) degraders as novel antitumor therapeutics leveraging our internal knowledge on Y-803 (birabresib, OTX015/MK-8628), which was discovered by our company as the first-in-class BRD4 inhibitor. Since we had obtained rich structure-activity relationship (SAR) information on its core skeleton, thienodiazepine, we designed and optimized Von Hippel-Lindau (VHL)-based BRD4 degraders based on the thienodiazepine scaffold. Here, we report that we obtained a novel, best-in-class BRD4 degrader, which showed a potent antitumor effect in a xenograft model of acute myeloid leukemia (AML).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsTranscription FactorsAntineoplastic AgentsDrug DiscoveryNuclear ProteinsBenzodiazepinonesBromodomain Containing ProteinsHumansStructure-Activity RelationshipAnimalsCell Line, TumorMiceMolecular StructureCell ProliferationLeukemia, Myeloid, AcuteDose-Response Relationship, DrugDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Acute myeloid leukemia (AML)BRD4Structure activity relationship (SAR)Targeted protein degradationThienodiazepineVHL

Substanzen

Bromodomain Containing ProteinsBRD4 protein, humanCell Cycle ProteinsTranscription FactorsAntineoplastic AgentsNuclear ProteinsBenzodiazepinones

Autor:innen und Institutionen

  • Research Division, Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: mayu.shigekuni@tanabe-pharma.com.
  • Research Division, Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: yasuki.niwa@tanabe-pharma.com.
  • Research Division, Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.
  • Research Division, Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: minoru.tanaka@tanabe-pharma.com.

Zitieren

APA

Shigekuni, M., Niwa, Y., Ohba, K., Hamada, M., Maruyama, H., Miyazaki, S., Iijima, D., Ooike, S., Fujita, R., Fukano, Y., Takahashi, T., Torimoto, N., Sakairi, T., Noguchi, K., Inoue, Y., & Tanaka, M. (2026). Discovery of a potent thienodiazepine derivative as a novel BRD4 degrader. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2026.118583

Vancouver

Shigekuni M, Niwa Y, Ohba K, Hamada M, Maruyama H, Miyazaki S, et al. Discovery of a potent thienodiazepine derivative as a novel BRD4 degrader. Bioorganic & Medicinal Chemistry. 2026. doi:10.1016/j.bmc.2026.118583

BibTeX
@article{Shigekuni2026,
  author = {Shigekuni, Mayu and Niwa, Yasuki and Ohba, Kiyomi and Hamada, Maiko and Maruyama, Hideto and Miyazaki, Shiki and Iijima, Daisuke and Ooike, Shinsuke and Fujita, Ryo and Fukano, Yasufumi and Takahashi, Tsuyoshi and Torimoto, Nao and Sakairi, Tetsuya and Noguchi, Koji and Inoue, Yuki and Tanaka, Minoru},
  title = {Discovery of a potent thienodiazepine derivative as a novel BRD4 degrader},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2026},
  doi = {10.1016/j.bmc.2026.118583}
}
Kostenlos starten →